ESC Professional Premium Access

Reduced dose, but not reduced risk: rates of inappropriate apixaban dose reduction and stroke and bleeding incidence

Congress Presentation

About the speaker

Doctor Josephine Harrington

Duke Clinical Research Institute, Durham (United States of America)
0 follower

7 more presentations in this session

Two-year effectiveness and safety outcomes in 27,333 edoxaban-treated patients with and without a history of major bleeding from the Global ETNA-AF programme

Speaker: Professor R. De Caterina (Pisa, IT)


D-dimer-driven versus standard prophylactic anticoagulation with fondaparinux in critically ill patients with COVID-19 and coagulopathy: an open-label, randomized controlled trial

Speaker: Doctor L. Adrian (Surabaya, ID)


Real-world effectiveness and safety of edoxaban in patients with and without a history of ischaemic stroke: results from the ETNA-AF programme

Speaker: Professor R. De Caterina (Pisa, IT)


Performance assessment of unfractionated heparin protocol in pediatric patients supported on extracorporeal membrane oxygenation

Speaker: Ms E. Shorog (Abha, SA)


Protective effect of proton pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: A systematic review and meta-analysis

Speaker: Doctor H. Ahn (Seoul, KR)


Access the full session

How to balance efficacy and safety of anticoagulant therapy in clinical practice

Speakers: Doctor J. Harrington, Professor R. De Caterina, Doctor L. Adrian, Professor R. De Caterina, Ms E. Shorog...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb